Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: transient receptor potential channel therapeutics - PharmEste

Drug Profile

Research programme: transient receptor potential channel therapeutics - PharmEste

Alternative Names: PHE 575; TRPA1 antagonists; TRPV1 antagonists

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmEste
  • Class
  • Mechanism of Action TRPA1 protein inhibitors; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Neuropathic pain; Overactive bladder; Respiratory tract disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in Italy
  • 04 Nov 2017 No recent reports of development identified for research development in Respiratory-tract-disorders in Italy
  • 24 May 2011 Research programme: transient receptor potential channel therapeutics - PharmEste is available for licensing as of 24 May 2011. http://www.pharmeste.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top